Joellen Schilkdraut

Professor

Emory University
Country flagUnited States
ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (29)

Background: Menstrual cycle characteristics—including age at menarche and cycle length— have been associated with ovarian cancer risk in White women. However, the associations between menstrual cycle characteristics and ovarian cancer risk among Black women have been sparsely studied. Methods: Using the Ovarian Cancer in Women of African Ancestry (OCWAA) Consortium that includes 1,024 Black and 2,910 White women diagnosed with epithelial ovarian cancer (EOC) and 2,325 Black and 7,549 White matched controls, we investigated associations between menstrual cycle characteristics (age at menarche, age at menstrual regularity, cycle length, and ever missing three periods) and EOC risk by race and menopausal status. Multivariable logistic regression was used to calculate odds ratios (OR) and 95% confidence intervals (CI). Results: Black women were more likely to be Conclusions: Earlier age at menarche and cycle irregularity are associated with increased EOC risk for White but not Black women. Impact: Associations between menstrual cycle characteristics and EOC risk were not uniform by race.

Year:

2025

Kaplan–Meier curves of OS in ( A ) main tumor groups ( n = 582)—MBOT, MOC, LGI, and UGI; ( B ) patients with MOC by FIGO stage ( n = 184); ( C ) patients with MOC by pattern of invasion in all stages ( n = 178); and ( D ) patients with stage I MOC ( n = 134), by pattern of invasion.

Year:

2025

Schema of study numbers for each analysis to describe different cohort numbers due to pathology review and missing data. MOC, mucinous ovarian carcinoma; MBOT, mucinous borderline ovarian tumor; LGI, lower gastrointestinal; UGI, upper gastrointestinal; SISH, silver in situ hybridization.

Year:

2025

Heat map of unsupervised clustering analysis. Contains all samples with a concordant pathology diagnosis ( n = 497), with MOC grouped by FIGO stage. Labels show main clusters and diagnoses. Gene-expression values are normalized and logarithm base 2 transformed. dx, diagnosis.

Year:

2025

Germline variants and somatic mutations in homologous recombination pathway genes prioritized in the 2020 American Society of Clinical Oncology (ASCO) recommendation for genetic testing in ovarian cancer

Year:

2025

Background: Half of ovarian high-grade serous carcinomas (HGSC) have homologous recombination deficiency (HRD). However, HRD is not well characterized in Black individuals who experience worse survival after a diagnosis of HGSC. The objective of this study was to characterize ovarian HGSC HRD and examine its association with survival by self-reported race. Methods: HRD features were identified using matched tumor–normal whole-exome and RNA sequencing in an HGSC cohort. We calculated age- and stage-adjusted HR and 95% confidence intervals (CI) for survival, comparing individuals with a feature to those without, separately by self-reported race. Results: Any HRD was associated with a 32% reduced risk of death in Black individuals compared with a 62% reduction in White individuals (Black HR = 0.68; 95% CI, 0.43–1.09; White HR = 0.38; 95% CI, 0.14–1.04). More of the germline and somatic variants detected among Black individuals were unannotated or variants of uncertain significance (VUS; germline 65% vs. 45%; somatic 62% vs. 50%). Black individuals with germline unannotated/VUS were more likely to have tumors with HRD scarring and a first-degree family history of breast or ovarian cancer compared with those without (HRD scar 71.4% vs. 49.6%; family history 68.4% vs. 34.6%). Conclusions: HRD testing informs precision-based medicine approaches that improve outcomes, but a higher proportion of VUS among Black individuals may complicate referral for such care leading to worse outcomes for Black individuals. Impact: Our findings emphasize the importance of recruiting diverse individuals in genomics research and better characterizing VUS.

Year:

2025

Background: Germline genetics may influence tumor molecular characteristics and ultimately cancer survival. Studies of tumor characteristics, including our epithelial ovarian cancer (EOC) studies of Black women in the United States, may have RNA sequencing (RNA-seq) data from archival tumor tissue but lack germline DNA for at least some individuals. Incomplete germline DNA measurements impede analyses of important measures such as global genetic ancestry, often used in downstream analyses, by reducing sample sizes. Methods: The study population consists of 184 women who participated in two population-based studies of EOC with both germline and formalin-fixed, paraffin-embedded (FFPE) tumor samples and an additional 58 women diagnosed with EOC from the same two studies with only FFPE tumor tissue. We used tumor RNA-seq data to calculate proportions of African, European, and Asian genetic ancestry using a pipeline built on the packages SeqKit, HISAT2, SAMtools, BCFtools, PLINK, and ADMIXTURE. Women from the 1000 Genomes Project were used as the reference populations, and germline genetic ancestry estimates from blood or saliva were used as the baseline comparison. We evaluated multiple quality control strategies to improve genetic ancestry estimation. Results: Correlations between tumor RNA-seq–derived estimates of genetic ancestry from our pipeline and germline-derived African and European genetic ancestry ranged between 0.76 and 0.94. Conclusions: RNA-seq data from archival FFPE tumor tissue can be confidently and efficiently used to approximate global genetic ancestry in an admixed population when germline DNA is unavailable. Impact: This approach supports analyses of genetic ancestry and cancer when germline samples are not available.

Year:

2025

Supplementary Table S2 shows the distribution of SNP type stratified by whether or not data from a participant's tumor sample met the proposed SNP threshold to improve genetic ancestry estimation and overall.

Year:

2025

Supplementary Figure S1 shows the difference in distributions of African genetic ancestry subpopulation proportions as calculated from germline DNA and tumor RNASeq (n = 184; ESN = Esan, GWD = Gambian, LWK = Luhya, MSL = Mende, YRI = Yoruba).

Year:

2025

Background: Germline alleles near genes encoding certain immune checkpoints (CTLA4, CD200) are associated with autoimmune/autoinflammatory disease and cancer, but in opposite ways. This motivates a systematic search for additional germline alleles with this pattern with the aim of identifying potential cancer immunotherapeutic targets using human genetics. Methods: Pairwise fixed effect cross-disorder meta-analyses combining genome-wide association studies (GWAS) for breast, prostate, ovarian and endometrial cancers (240,540 cases/317,000 controls) and seven autoimmune/autoinflammatory diseases (112,631 cases/895,386 controls) coupled with in silico follow-up. Results: Meta-analyses followed by linkage disequilibrium clumping identified 312 unique, independent lead variants with p 0.5) with at least one intra-tumor T/myeloid cell infiltration marker (CD4, CD8A, CD11B, CD45) in every one of the cancer types. Tumor single-cell RNA-Seq data from all cancer types showed that the five genes were more likely to be expressed in intra-tumor immune versus malignant cells. The five lead SNPs corresponding to these genes were linked to them via the expression of quantitative trait locus mechanisms and at least one additional line of functional evidence. Proteins encoded by the genes were predicted to be druggable. Conclusions: We provide population-scale germline genetic and functional genomic evidence to support further evaluation of the proteins encoded by IRF1, IKZF1, SPI1, SH2B3 and LAT as possible targets for cancer immunotherapy.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (82)

Charlie Gourley

University of Edinburgh

UNITED KINGDOM
View details

Patricia Moorman

Professor

Duke University

UNITED STATES
View details

Sue K. Park

Professor

Seoul National University College of Medicine

SOUTH KOREA
View details

Lynn Rosenberg

Boston University

UNITED STATES
View details

Heather Wheeler

Professor

Loyola University Chicago

UNITED STATES
View details

Hae Kyung Im

University of Chicago

UNITED STATES
View details

Kathryn Terry

Co-Scientific Director

Boston Children's Hospital

UNITED STATES
View details

Elizabeth Christie

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Timothy Budden

Lecturer

University of Liverpool

UNITED KINGDOM
View details

Lucas A Salas

Assistant Professor

Dartmouth College Geisel School of Medicine

UNITED STATES
View details

Beth Karlan

Vice Chair

University of California, Los Angeles

UNITED STATES
View details

Chad Huff

Professor

The University of Texas MD Anderson Cancer Center

UNITED STATES
View details

Anna Jakubowska

Head

Pomeranian Medical University

POLAND
View details

Lynne Wilkens

Professor

University of Hawaii at Manoa

UNITED STATES
View details

Anthony Swerdlow

Professor of Epidemiology

Institute of Cancer Research Sutton

UNITED KINGDOM
View details

Heather M Ochs-Balcom

Professor & Associate Chair

University at Buffalo

UNITED STATES
View details

Matthew Wakefield

University of Melbourne

AUSTRALIA
View details

Martin Widschwendter

Professor; Director

University of Innsbruck

AUSTRIA
View details

P. M. Webb

Group Leader

QIMR Berghofer Medical Research Institute

AUSTRALIA
View details

Martin Köbel

Associate Professor

University of Calgary

CANADA
View details

Gregory Way

Associate Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Estrid V. Hoegdall

University of Copenhagen

DENMARK
View details

Siddhartha P Kar

University Associate Professor

University of Cambridge

UNITED KINGDOM
View details

Paul Timpson

Co-Director ACRF (INCITe) Centre

Garvan Institute of Medical Research

AUSTRALIA
View details

James D Brenton

University of Cambridge

UNITED KINGDOM
View details

Jae-Weon Kim

Professor

Seoul National University Hospital

SOUTH KOREA
View details

Cezary Cybulski

Pomeranian Medical University

POLAND
View details

Lyndal Anderson

University of Western Sydney

AUSTRALIA
View details

Claus Høgdall

Professor in Clinical Gynecologic Oncology

University of Copenhagen

DENMARK
View details

Lindsay J Collin

Assistant Professor

Emory University

UNITED STATES
View details

Anthony Gill

University of Sydney

AUSTRALIA
View details

Linda Cook

Professor

University of Colorado Cancer Center

UNITED STATES
View details

Paul James

Head of Adult Genetics

The Royal Melbourne Hospital Royal Park Campus

AUSTRALIA
View details

Parham Minoo

Associate Clinical Professor of Pathology

University of Calgary

CANADA
View details

Angela Brooks-Wilson

Simon Fraser University

CANADA
View details

Tomasz Kluz

Professor

Rzeszów University

POLAND
View details

Michael Anglesio

Associate Professor

The University of British Columbia

CANADA
View details

Ramona Erber

W2-Professorin, Oberärztin

University of Regensburg

GERMANY
View details

Nicholas Hawkins

Emeritus Professor

UNSW Sydney

AUSTRALIA
View details

Usha Menon

Professor of Gynaecological Oncology

University College London

UNITED KINGDOM
View details

Kristin Guertin

Assistant Professor

University of Connecticut

UNITED STATES
View details

Evan Myers

Duke University

UNITED STATES
View details

Michael P Epstein

Emory University School of Medicine

UNITED STATES
View details

Sandra Orsulic

Professor

University of California, Los Angeles

UNITED STATES
View details

Cheng-Han Lee

Associate Professor

University of Alberta

CANADA
View details

Casey Greene

Director

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Ian Campbell

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Stacey J. Winham

Mayo Clinic College of Medicine and Science

UNITED STATES
View details

Jae-Hoon Kim

Yonsei University College of Medicine

SOUTH KOREA
View details

Anna H. Wu

Professor

University of Southern California

UNITED STATES
View details

C Blake Gilks

-

CANADA
View details

Peter Fasching

-

GERMANY
View details

Francesmary Modugno

University of Pittsburgh

UNITED STATES
View details

Alexander Hein

-

GERMANY
View details

Kylie-Ann Mallitt

Senior Lecturer in Biostatistics

University of Sydney

AUSTRALIA
View details

Dale Garsed

University of Melbourne

AUSTRALIA
View details

Philip Crowe

Professor Surgery

University of New South Wales

AUSTRALIA
View details

Renée Fortner

Head of Division

Deutsches Krebsforschungszentrum

GERMANY
View details

K Sundfeldt

Professor/Consultant

University of Gothenburg, Sahlgrenska Academy

SWEDEN
View details

Tomasz Huzarski

Pomeranian Medical University

POLAND
View details

Byoung-Gie Kim

Sungkyunkwan University School of Medicine

SOUTH KOREA
View details

Dane Cheasley

Senior Research Fellow

University in Western Australia

AUSTRALIA
View details

Gregg Nelson

Gynecologic Oncologist

University of Calgary

CANADA
View details

Jennifer Anne Doherty

Professor

University of Utah

UNITED STATES
View details

Paul Pharoah

Professor of Cancer Epidemiology

Cedars-Sinai Medical Center

UNITED STATES
View details

Brenda Y Hernandez

University of Hawaii

UNITED STATES
View details

Natalie Davidson

Assistant Professor

University of Colorado Anschutz Medical Campus

UNITED STATES
View details

Michael Edwin Jones

Senior Staff Scientist

Institute of Cancer Research

UNITED KINGDOM
View details

Kylie L Gorringe

Group Leader

Peter MacCallum Cancer Institute

AUSTRALIA
View details

Jan Lubiński

Head of Dept

Pomeranian Medical University

POLAND
View details

Veronica Setiawan

Associate Professor

University of Southern California

UNITED STATES
View details

Mona El-Bahrawy

Imperial College London

UNITED KINGDOM
View details

Aleksandra Gentry-Maharaj

University College London

UNITED KINGDOM
View details

David G. Huntsman

The University of British Columbia

CANADA
View details

Janusz Menkiszak

Head of the University Clinic

Pomeranian Medical University

POLAND
View details

Clare Scott

Walter and Eliza Hall Institute of Medical Research

AUSTRALIA
View details

Elisa Bandera

Chief

Rutgers Cancer Institute of New Jersey

UNITED STATES
View details

Susan Ramus

Professor of Molecular Oncology

University of New South Wales

AUSTRALIA
View details

Paul Cohen

University of Western Australia

AUSTRALIA
View details

Aline Talhouk

Assistant Professor

The University of British Columbia

CANADA
View details

Charlotte Joslin

University of Illinois Chicago (UIC)

UNITED STATES
View details

David Lawson Morris

Professor of Surgery

University of New South Wales

AUSTRALIA
View details